Search company, investor...

Torii Pharmaceutical Co.

torii.co.jp

Stage

IPO | IPO

Date of IPO

6/1/1963

Market Cap

78.96B

About Torii Pharmaceutical Co.

Torii Pharmaceutical specializes in the manufacturing and marketing of pharmaceutical products. It is based in Chuo-Ku, Japan.

Headquarters Location

4-1, Nihonbashi-Honcho 3-chome Chuo-ku

Tokyo, 103-8439,

Japan

Missing: Torii Pharmaceutical Co.'s Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Torii Pharmaceutical Co.'s Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Torii Pharmaceutical Co. Patents

Torii Pharmaceutical Co. has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/29/2019

Clusters of differentiation, Immunology, Immune system, Autoimmune diseases, Oncology

Application

Application Date

11/29/2019

Grant Date

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Autoimmune diseases, Oncology

Status

Application

Latest Torii Pharmaceutical Co. News

Torii Pharmaceutical : Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl Hydrocarbon Receptor (AhR) Agonist, in Patients with Plaque Psoriasis in Japan(PDF)

Sep 16, 2022

09/16/2022 | 02:10am EDT Message : Tokyo, September 16, 2022 Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl Hydrocarbon Receptor (AhR) Agonist, in Patients with Plaque Psoriasis in Japan Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced today the positive top-line results of a Phase 3 comparative study for JTE-061, conducted in Japan, for the treatment of plaque psoriasis. JT signed an exclusive license agreement with Dermavant Sciences GmbH (Dermavant) for the development and commercialization of tapinarof, a topical, therapeutic aryl hydrocarbon receptor agonist (JTE-061), for dermatological diseases and conditions in Japan. JT also signed an exclusive license agreement with Torii for co-development and commercialization of JTE-061 in Japan. JTE-061 is being developed for patients with atopic dermatitis and plaque psoriasis. This study is a double blind, randomized, parallel-group comparison study to evaluate the efficacy and safety of JTE-061 cream in comparison to vehicle over 12 weeks in patients with plaque psoriasis. The top-line results show that the PGA response1 at week 12, the primary endpoint of efficacy, has achieved statistical significance in comparison to vehicle. The safety of JTE-061 cream was confirmed and there were no observed issues of tolerability for the cream. JT and Torii will aim to submit a manufacturing and marketing application for JTE-061 cream in Japan, based on the results of the study and other Phase 3 studies currently being conducted. Separately, Phase 3 clinical studies in adult and adolescent patients with atopic dermatitis and Phase 2 clinical studies in pediatric patients (aged 2 to ≤11 years) with atopic dermatitis are ongoing and being conducted in Japan. Tapinarof cream is developed by Dermavant and was approved for the treatment of plaque psoriasis on May 23, 2022 in the U.S. ABOUT Plaque Psoriasis Plaque Psoriasis is a chronic, systemic, inflammatory skin disease characterized by red patches and plaques with silvery scales on the skin. 1 Proportion of subjects which achieve a Physician Global Assessment (PGA) score of 0 (Clear) or 1 (Almost clear) with a minimum of 2-grade improvement from baseline. PGA score is a tool used to measure the extent area and severity of plaque psoriasis (IGA=0: Clear, 1: Almost clear, 2: Mild, 3: Moderate, 4: Severe). ABOUT Atopic Dermatitis Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritation or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function). ### Japan Tobacco Inc. is a leading international tobacco company selling its products in more than 130 countries and regions. With approximately 55,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jt.com/ . Contact for Japan Tobacco Inc.: Contact for Torii Pharmaceutical Co., Ltd.: Dinesh Babu Thotakura, General Manager Corporate Planning Department

Torii Pharmaceutical Co. Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Torii Pharmaceutical Co. Rank

Torii Pharmaceutical Co. Frequently Asked Questions (FAQ)

  • Where is Torii Pharmaceutical Co.'s headquarters?

    Torii Pharmaceutical Co.'s headquarters is located at 4-1, Nihonbashi-Honcho 3-chome, Tokyo.

  • What is Torii Pharmaceutical Co.'s latest funding round?

    Torii Pharmaceutical Co.'s latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.